RGBPP News and Press, Regen BioPharma From 03/10/22

Regen BioPharma, Inc. Announces Program to Fast-Track its Checkpoint Inhibitor Program Utilizing Modified mRNA and siRNA Technologies PR Newswire SAN DIEGO , March 10, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) announced a progr...

SAN FRANCISCO, CA / ACCESSWIRE / February 14, 2022 / Oncology Pharma, Inc. ("The Company") (OTC PINK:ONPH) and Regen BioPharma, Inc. (OTC PINK:RGBP) and (OTC PINK:RGBPP): announced that they intend to work jointly to fast track the development of therapeutic uses related to treatment in huma...

Regen BioPharma, Inc. to Initiate Development of its Modified mRNA anti-Cancer Vaccine Technology PR Newswire SAN DIEGO , Feb. 11, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP) is embarking on a development program to commercializ...

REGEN BIOPHARMA, INC.: MESSAGE TO THE SHAREHOLDERS FROM THE CHAIRMAN AND CHIEF EXECUTIVE OFFICER PR Newswire SAN DIEGO , Dec. 30, 2021 /PRNewswire/ -- Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP): First of all I would like to wish all our sharehol...

Regen BioPharma, Inc. Announces Signing of a Letter of Intent to Acquire an In vitro Diagnostics Start-Up Company Canary Oncoceutics, Inc. Which is Developing Functional Cancer Tests for Personalized Medicine PR Newswire SAN DIEGO , Nov. 17, 2021 /PRNewswire/ --&...

SAN DIEGO , Nov. 1, 2019 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) announced today new data demonstrating that suppression of NR2F6 using patent-pending compounds developed by the Company results in selective inhibition of new blood vessels under condit...

SAN DIEGO , Oct. 3, 2019 /PRNewswire/ -- Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), announced today positive data demonstrating that its novel cannabidiol-based therapeutic approach successfully reduces rheumatoid arthritis in an animal model. The data disclosed today, wh...

SAN DIEGO , Aug. 15, 2019 /PRNewswire/ -- Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP),  announced today data demonstrating its unique combination of NR2F6 inhibition together with cannabidiol decreases cancer metastasis in an animal model of cancer surgery. These exper...

SAN DIEGO , Aug. 7, 2019 /PRNewswire/ -- Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP),  announced today filing of a US patent application covering a newly discovered synergy between inhibition of NR2F6 and cannabidiol (CBD). The new data demonstrates enhanced ability to redu...

SAN DIEGO , May 8, 2019 /PRNewswire/ -- Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP), has received a number of inquiries regarding a potential reverse merger with another biotechnology related company. Responding to these inquiries the Company reports that it is currently not in...